Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors
Public ClinicalTrials.gov record NCT02988817. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of Axl-specific Antibody-drug Conjugate (Enapotamab Vedotin, HuMax®-AXL-ADC) in Patients With Solid Tumors
Study identification
- NCT ID
- NCT02988817
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Genmab
- Industry
- Enrollment
- 306 participants
Conditions and interventions
Conditions
Interventions
- Enapotamab vedotin (HuMax-AXL-ADC) Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 22, 2016
- Primary completion
- Nov 11, 2021
- Completion
- Nov 11, 2021
- Last update posted
- Jul 31, 2023
2016 – 2021
United States locations
- U.S. sites
- 20
- U.S. states
- 16
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic - Phoenix | Phoenix | Arizona | 85054 | — |
| University of Colorado Hospital | Aurora | Colorado | 80045 | — |
| Yale University, Smilow Cancer Center at Yale New Haven Hospital | New Haven | Connecticut | 06520 | — |
| Mayo Clinic Jacksonville | Jacksonville | Florida | 32224 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Emory University School of Medicine, Winship Cancer Institute | Atlanta | Georgia | 30322 | — |
| University of Iowa | Iowa City | Iowa | 52242 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02115 | — |
| University of Michigan Comprehensive Cancer Center | Ann Arbor | Michigan | 48109 | — |
| Mayo Clinic Rochester | Rochester | Minnesota | 55905 | — |
| Washington University | St Louis | Missouri | 63110 | — |
| Roswell Park Comprehensive Cancer Center | Buffalo | New York | 14263 | — |
| Laura and Isaac Perlmutter Cancer Center at NYU Langone | New York | New York | 10016 | — |
| Herbert Irving Comprehensive Cancer Center | New York | New York | 10034 | — |
| Duke Cancer Institute | Durham | North Carolina | 27710 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| Mary Crowley Cancer Research Center | Dallas | Texas | 75230 | — |
| University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| University of Utah Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | — |
| University of Wisconsin Carbone Cancer Center | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 21 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02988817, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 31, 2023 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02988817 live on ClinicalTrials.gov.